报告题目： Targeted Eradication of Malignant Cerebral Tumor

报告人：姜新义 教授

邀请人：王飞虎 博士

报告时间： 3月 30日（周四） 14:00-15:40

地点：徐汇校区工程馆100室

摘要：  

Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, which is highly invasive. Surgical debulking is the first clinical intervention for GBM patient. However, GBM shows invasive growth, has no obvious boundary with normal brain tissue, and cannot be completely removed by surgery. The residual tumor cells after surgery still have strong proliferative capacity, are insensitive to radiotherapy and chemotherapy, and eventually lead to rapid recurrence of brain tumors within a few months. To explore an effective strategy of "specifically" eliminating invasive brain tumors is the key to prevent recurrence after GBM. Immunotherapy has brought unprecedented changes and hopes for cancer treatment. However, there is no successful immunotherapy program for GBM at present. Through the analysis of clinical samples of GBM patients, we confirmed that the expression levels of multiple biomarkers such as IDH1, IDO1 and CD133 in malignant brain tumor tissues were significantly increased, and were negatively correlated with the survival of patients. In view of this, we have constructed two nanocarrier-hydrogel superstructure drug delivery systems that can reshape the tumor immune microenvironment in situ to curb the recurrence of GBM after surgery: (i) induce immunogenic death, activate and recruit T lymphocytes, silence IDO1 to relieve the function and efficiency of Treg cell immune "brake", cascade to reshape the tumor killing immune microenvironment, and curb the recurrence of GBM after surgery; (ii) Generate CAR macrophages around the tumor cavity in vivo that can target the removal of glioma stem cells (GSCs), activate the adaptive immune system by its antigen presentation, remove residual GSCs after surgery, and avoid GBM tumor recurrence. Intracavity drug delivery offers a convenient and effective approach that can be seamlessly integrated with clinical surgical debulking without the need for additional surgery.

主讲人简介：姜新义，山东大学教授、药剂学博士生导师，入选国家优秀青年人才项目，山东省高校“智能材料与药物递送”青创团队带头人，山东大学杰出中青年学者，山东大学“齐鲁青年学者”，山东大学药学院“智能材料与药物精准递送”团队PI。

2013-2017年任Stanford University医学院博士后研究员；2017年全职回国，先后承担国家及省部级重点重大等课题10余项；已在Nature Nanotechnology，Science Translational Medicine，Nature Communications，PNAS，Science Advances，Advanced Materials，ACS Nano等学术期刊上发表研论文50余篇；申报国家发明专利 20余项、PCT专利3项，10项已获授权，9项已转让。应邀在国际控释协会、中国药学大会、生物医学工程BMES等国内外学术会议上做口头报告30余次，先后获得国际先进材料协会科学家奖（2021），入选国际先进材料协会会士（2022），山东省医学科技二等奖；指导研究生获得全国药学专业学位研究生优秀学位论文，山东省研究生优秀成果一等奖等荣誉。目前担任中国药学会-药剂专业委员会青年委员，中国颗粒学会-生物颗粒专业委员会委员，中国颗粒学会第三届青年理事会理事，中国医药教育协会中药制剂专业委员会常务委员, 山东省医药生物技术学会-细胞治疗技术与标准化专业委员会委员；同时担任Nature Nanotechnology，Science Translational Medicine，Nature Communications，PNAS，Advanced Materials等30余个知名期刊特约审稿人。